# | Namea [ref.] | Alternative name [ref.] | Base changeb | DNA or protein sequencingc | Intron/Exon | Protein changed | Notes and functional effects [ref.] |
1 | Malmö I [1] | Kaikoura, Tradate [1], Redhill (see also residue 320) [2-4], Sweden [5], Ildut [6] | c.67C>T | D/P | E-1 | –2Arg→Cys | Malmö I: 3% proalbumin, 30% Arg-albumin (due to aberrant signal peptide cleavage) with the rest as normal albumin (Alb A) [1]. Sweden: 3 homozygotes [5] |
2 | Lille [7] | Pollibauer [8],Somalia, Tokushima [9],Taipei [10], Fukuoka-2 [11],Varese [12], Wu Yang [13], Mayo EW220, Komagone-3 [14], Stirling [15] | c.68G>A | P | E-1 | –2Arg→His | |
3 | Christchurch [16] | Gainesville, Y [10,17], Honolulu-2 [18], Fukuoka-3 [11], Mayo JW180 [14], Shizuoka [19], Kamloops [15], Zagreb [20,21] | c.71G>A | P | E-1 | –1Arg→ Gln | |
4 | Takefu [10] | Honolulu-1 [18] | c.71G>C | P | E-1 | –1Arg→Pro | |
5 | Jaffna [22] | c.71G>T | P | E-1 | –1Arg→ Leu | ||
6 | Blenheim[23] | Bremen [18], Malmö II, Iowa City-2 [14] | c.74A>T | P | E-1 | 1Asp→ Val | Blenheim: 10% proalbumin, 38% Val- [23]. Bremen: 20% Arg-Alb, 30% Val- [1]. In both cases, the remaining is Alb A. Blenheim: decreased α-helical content [24]. |
7 | Larino [25] | c.79C>T | D/P | E-1 | 3His→Tyr | Low in vivo stability [25] | |
8 | Nagasaki-3 [10] | c.81C>A/G | P | E-2 | 3His→Gln | ||
9 | Torino [12] | c.250G>A | P | E-3 | 60Glu→Lys | ||
10 | Dalakarlia-1 [5,26] | Sweden-1, Malmö-95 | c.259G>A | D/P | E-3 | 63Asp→Asn; N-glycosylated at 63Asn | CHO next to a Cys. High thermal stability [24]. Decreased α-helical content [24] |
11 | FDH-T3 [27] | c.269T>C | D | E-3 | 66Leu→Pro | High T3 binding. Identified in a Thai family. | |
12 | Vibo Valentia [12] | c.316G>A | P | E-4 | 82Glu→Lys | ||
13 | Yanomama-2 [28] | c.412C>G | P | E-4 | 114Arg→Gly | Low bilirubin binding [29] | |
14 | Nagoya [18] | c.427G>A | P | E-4 | 119Glu→Lys | ||
15 | Tregasio [30] | c.437T>A | P | E-4 | 122Val→Glu | Decreased plasma half-life [31] | |
16 | Komagome-2 [14] | c.455A>G | P | E-4 | 128His→Arg | ||
17 | Asola [32] | c.491A>G | D/P | E-5 | 140Tyr→Cys | 20-25% variant [32] | |
18 | Korea [33] | c.593A>T | D | E-5 | 174Lys→Ile | ||
19 | Hawkes Bay [34] | c.602G>T | D/P | E-5 | 177Cys→Phe | 5% variant [34]. Decreased α-helical content [24]. Decreased plasma half-life [31] | |
20 | Ilam [88] | c.643G>A | D/P | E-6 | 191Ala→Thr | Identified by a new high resolution on-line reverse phase time-of-flight mass spectrometry procedure. | |
21 | FDH-3 [89] | c.724C>A | D | E-7 | 218Arg→Ser | High free T4 andT3. Identified in a Canadian family of Bangladeshi extraction. | |
22 | FDH-1 [35,36] | c.725G>A | D | E-7 | 218Arg→His | High T4 binding [35-37]. Low warfarin binding [38].The most common causal variant in Caucasians [35]. | |
23 | FDH-2 [39,40] | c.725G>C | D | E-7 | 218Arg→Pro | High T4 binding [39,40]. Low warfarin binding [38]]. Identified in Japanese and Swiss subjects [39,40]. | |
24 | FDH-4 [90] | c.737G>T | D | E-7 | 222Arg→Ile | High T4 binding. Identified in three unrelated African (Somali) families and one East European (Croatian) family. | |
25 | Tradate-2 [25] | Vera Cruz [41] | c.745A>C | D/P | E-7 | 225Lys→Gln | |
26 | Herborn [42] | c.790A>G | P | E-7 | 240Lys→Glu | ||
27 | Skaane [5] | c.875A>G | D/P | E-8 | 268Gln→Arg | ||
28 | Niigata [43] | Nagasaki-1 [19] | c.878A>G | P | E-8 | 269 Asp→Gly | High prostaglandin binding [44] |
29 | Caserta [25] | c.900G>C | D/P | E-8 | 276 Lys→Asn | 60-70% variant [25] | |
30 | Tagliacozzo [25,45] | Cuneo [25], Cooperstown [46], Canterbury [47], New Guinea [18], Reading [48], IRE-1 [49], Sweden [5] | c.1011G>T | D/P | E-8 | 313 Lys→Asn | Low drug binding [50]. Low thermal stability [24]. High progesterone binding [44] |
31 | Bergamo [30] | c.1013A>G | P | E-8 | 314 Asp→Gly | ||
32 | Brest [6] | c.1013A>T | P | E-8 | 314Asp→Val | High fatty acid binding [6] | |
33 | Orebro [5] | Malmo-4 [5] | c.1026C>G | D/P | E-8 | 318 Asn→Lys | |
34 | Redhill [2-4] | c.[67C>T (=Malmö-I); 1030G>A] | D/P | E-1; E-8 | ‒2Arg→Cys (=Malmö-I); 320 Ala→Thr; N-glycosylated at 318Asn (AsnTyrThr) [4,51] | High fatty acid binding [52] | |
35 | Roma [53] | c.1033G>A | P | E-8 | 321Glu→Lys | Low testosterone binding [44] | |
36 | Sondrio [54,55] | c.1069G>A | P | E-9 | 333Glu→Lys | ||
37 | Hiroshima-1 [19] | c.1132G>A | P | E-9 | 354Glu→Lys | ||
38 | Coari I [56] | Porto Alegre I [56] | c.1144G>A | D/P | E-9 | 358Glu→Lys | |
39 | Trieste [57] | c.1149G>T/C | P | E-9 | 359 Lys→Asn | Low thermal stability [24] | |
40 | Parklands [58] | c.1165G>C | P | E-9 | 365Asp→His | Low drug binding [50] | |
41 | Iowa City-1 [14] | c.1166A>T | P | E-9 | 365Asp→Val | ||
42 | Benkovac [59] | c.1175A>G | D | E-9 | 368Glu→Gly | ||
43 | Naskapi [60] | Mersin [61], Komagone-1 [14] | c.1186A>G | D/P | E-9 | 372Lys→Glu | |
44 | Nagasaki-2 [28] | Passo Fundo [41] | c.1195G>A | P | E-10 | 375 Asp→Asn | |
45 | Milano slow [57] | c.1195G>C | D/P | E-10 | 375Asp→His | ||
46 | Tochigi [19] | c.1198G>A | P | E-10 | 376Glu→Lys | ||
47 | Malmo-3 [5] | c.1198G>C | D/P | E-10 | 376Glu→Gln | ||
48 | Hiroshima-2 [19] | c.1216G>A | P | E-10 | 382Glu→Lys | ||
49 | Liprizzi [57,62] | c.1300C>T | D/P | E-11 | 410 Arg→Cys | High S-nitrosylation [63] | |
50 | Dublin [49] | c.1507G>A | P | E-12 | 479Glu→Lys | ||
51 | Casebrook [64] | Besana Brianza [30] | c.1552G>A | D/P | E-12 | 494 Asp→Asn; N-glycosylated at 494Asn (AsnGluThr) [65] | High fatty acid binding [52]. Decreased α-helical content [66] |
52 | Vancouver [67] | Birmingham, Adana [67], Porto Alegre II [56], Manaus I [18], Lambadi [18], Kashmir [68,69], Fortaleza [41] | c.1573G>A | D/P | E-12 | 501Glu→Lys | |
53 | Ortonovo [70] | c.1585G>A | P | E-12 | 505Glu→Lys | ||
54 | Lyon [71] | c.1601A>G | D/P | E-12 | 510His→Arg | ||
55 | Maddaloni [30] | c.1669G>A | P | E-13 | 533Val→Met | ||
56 | Castel di Sangro [72] | c.1678A>G | P | E-13 | 536Lys→Glu | ||
57 | South Pacific (see also residue 546) [73] | c.1690A>G | D/P | E-13 | 540 Thr→Ala | ||
58 | Maku, (Wapishana) [28] | Oriximina I [56] | c.1693A>G | D/P | E-13 | 541Lys→Glu | High fatty acid binding [52]. High thermal stability [24] |
59 | South Pacific [73] | c.1708G>T | D/P | E-13 | 546 Ala→Ser | ||
60 | Mexico [61] | c.1721A>G | D/P | E-13 | 550 Asp→Gly | ||
61 | Dalakarlia-2 [5] | Malmö-62 [5] | c.1721A>C | D/P | E-13 | 550Asp→Ala | |
62 | Church Bay [74] | c.1750A>G | D/P | E-13 | 560Lys→Glu | ||
63 | Fukuoka-1 [18] | Ube-1 [18], Varese-2 [75], Paris-2 [25,55] | c.1759G>A | D/P | E-13 | 563 Asp→Asn | High fatty acid binding [52]. Decreased α-helical content [24] |
64 | Osaka-1 [18] | c.1765G>A | D/P | E-13 | 565Glu→Lys | ||
65 | Bazzano [25] | c.1771delT | D/P | E-13 | (567)CFAEEGKKLVAASQAALGL (585) → (567)ALPRRVKNLLLQVKLP(582) | High fatty acid binding [52]. Decreased α-helical content [66] | |
66 | B [76,77,11] | Oliphant, Ann Arbor [78], Verona [25,79], Osaka-2, Phnom Penh, Nagano, London (Ontario), Lübeck, Tokyo-1, Shinanomachi-1 [11], Iowa City-3, Mayo (MT610, RW246 and SH420), Victoria (East India), [14], Saitama-1 [19], Sweden [5], Amsterdam [15] | c.1780G>A | D/P | E-13 | 570Glu→Lys | Low thermal stability [24] |
67 | Rugby Park [80] | c.1785+1G>C | D/P | I-13 | (572)GKKLVAASQAALGL (585) → (572)LLQFSSF(578) | 8% variant [80]. High fatty acid binding [52] | |
68 | Banks Peninsula [81] | c.1786-15T>A | D/P | I-13 | (572)GKKLVAASQAALGL (585) → (572)SLCSG(576) | ||
69 | Milano fast (Mi/Fg) [82, 25] | Krapina [21] | c.1789A>G | D/P | E-14 | 573Lys→Glu | This variant was recently identified in a 4-year-old Yemeni girl with growth hormone deficiency [91]. |
70 | Vanves [79] | c.1794A>T/C | D/P | E-14 | 574 Lys→Asn | ||
71 | Kénitra [83] | c.1794dupA | D/P | E-14 | (575)LVAASQAALGL (585) →(575)TCCCKSSCLRLITSHLKASQPTMRIRERK(603), 2 new SS bonds, T596 is half O-glycosylated | 15% variant [83]. Low thermal stability [24] | |
72 | Catania (Ge/Ct) [84,85] | c.1810delC | D/P | E-14 | (580)QAALGL(585) → (580)KLP (582) | ||
73 | Venezia [85,86] | c.1786_1814+1 delinsAAAAT | D/P | E-14/ I-14 | (572)GKKLVAASQAALGL(585) → (572)PTMRIRE (R)(K)(580) | 30% variant [86]. Low thermal stability [24]. Increased α-helical content [66]. Decreased plasma half-life [66] | |
A general feature of the variants modified close to the normal N-terminus (#1-8) is a low affinity for metal ions such as Cu++ and Ni++ [75]. For additional effects of a propeptide on the structure, stability and function on Alb A, see [75].
aThe variants have usually been named after the place from where the first detected carrier originates. bCodon numbering according to HGVS rules and based on the cDNA sequence NM_000477.7. For converting the present numbering to that of Minghetti et al. [87], see [75]. cThe structural changes have been determined by DNA (D) or protein (P) sequence analysis. dThe positions of proalbumin are from –6 to –1 (the juxtaposition to albumin itself), and those of the mature albumin molecule (Alb A) are from 1 to 585. Addition of 24 to these numbers converts them to a number according to HGVS rules, which is based on the preproalbumin sequence (NCBI Reference Sequence: NP_000468.1). |
REVISED 22.01.2021